Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD22/CD3 bispecific antibody JNJ-75348780

A human bispecific antibody, with potential antineoplastic activity. Anti-CD22/CD3 bispecific antibody JNJ-75348780 contains two binding sites, one for the tumor-associated antigen (TAA) CD22, and one for the T-cell surface antigen CD3. Upon administration, JNJ-75348780 binds to both CD3 on T cells and CD22-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD22-expressing tumor B cells. CD22 is exclusively expressed on B cells and is often overexpressed in B-lymphocytic malignancies. It negatively regulates the B-cell receptor.
Synonym:CD22 x CD3 bispecific antibody JNJ-75348780
Code name:JNJ 75348780
JNJ-75348780
JNJ75348780
Search NCI's Drug Dictionary